In Vivo Evidence Of Cftr Activation By Roflumilast: A Potential Mechanism Underlying Therapeutic Benefit Of Roflumilast In COPD

被引：0
|
作者：
Raju, S. [1 ]
Tang, L. [1 ]
Rowe, S. M. [1 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6013
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cftr Activation By Roflumilast: A Potential Mechanism Underlying Therapeutic Benefit Of Roflumilast In COPD
    Lambert, J. A.
    Raju, S. V.
    Courville, C.
    Tang, L.
    Mazur, M.
    Bolger, G. B.
    Rowe, S. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [2] CFTR ACTIVATION BY ROFLUMILAST CONTRIBUTES TO THERAPEUTIC BENEFIT IN CHRONIC BRONCHITIS
    Lambert, J. A.
    Raju, S., V
    Farris, R.
    Tang, L.
    Li, Y.
    Courville, C.
    Coricor, G.
    Smoot, L.
    Mazur, M.
    Dransfield, M.
    Bolger, G.
    Rowe, S. M.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 225 - 226
  • [3] Roflumilast: clinical benefit in patients suffering from COPD
    Ulrik, Charlotte Suppli
    Calverley, Peter Michael Anthony
    CLINICAL RESPIRATORY JOURNAL, 2010, 4 (04): : 197 - 201
  • [4] New therapeutic options in the management of COPD - focus on roflumilast
    Antoniu, Sabina Antonela
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2011, 6 : 147 - 155
  • [5] Cystic Fibrosis Transmembrane Conductance Regulator Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic Bronchitis
    Lambert, James A.
    Raju, S. Vamsee
    Tang, Li Ping
    McNicholas, Carmel M.
    Li, Yao
    Courville, Clifford A.
    Farris, Roopan F.
    Coricor, George E.
    Smoot, Lisa H.
    Mazur, Marina M.
    Dransfield, Mark T.
    Bolger, Graeme B.
    Rowe, Steven M.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2014, 50 (03) : 549 - 558
  • [6] Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap
    Zhang, Xiaoli
    Chen, Yuqing
    Fan, Liyu
    Ye, Jiaqi
    Fan, Junsheng
    Xu, Xinjie
    You, Danming
    Liu, Sihan
    Chen, Xin
    Luo, Peng
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 2371 - 2379
  • [7] Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
    Milo A. Puhan
    Tsung Yu
    Cynthia M. Boyd
    Gerben ter Riet
    BMC Medicine, 13
  • [8] Therapeutic Potential Of Inhaled Roflumilast N-Oxide In Airway Disorders
    Viswanadha, S.
    Routhu, K.
    Khapra, P.
    Raval, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [9] Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD
    Puhan, Milo A.
    Yu, Tsung
    Boyd, Cynthia M.
    ter Riet, Gerben
    BMC MEDICINE, 2015, 13
  • [10] Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis
    Yuan, Lianfang
    Dai, Xuan
    Yang, Meng
    Cai, Qiling
    Shao, Na
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 1477 - 1483
12345